Jounce Therapeutics

Jounce Therapeutics

Jounce Therapeutics is an immunotherapy company developing therapies to cancer founded in 2013 by James P. Allison, Drew Pardoll, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber and Thomas F. Gajewski.

Jounce Therapeutics is a publicly funded, clinical-stage immunotherapy company based in Cambridge, Massachusetts that was founded in 2013 by Drew Pardoll, James P. Allison, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber, and Thomas F. Gajewski. The company is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.

Products

JTX-2011

Jounce's lead product candidate is JTX-2011, a monoclonal antibody that binds to and activates the Inducible T-Cell Co-Stimulator (ICOS), a protein on the surface of certain T-cells that is believed will stimulate an immune response against a patient's cancer. It is intended to treat solid tumors as a single agent and in combination with other therapies. JTX-2011 is being evaluated in Phase 2 clinical trials.

JTX-8064

Another product candidate in Jounce's pipeline is JTX-8064. It is the company's lead Beyond T-cell program aimed at disrupting the interaction of targets on tumor-associated macrophages (TAMs) to skew the composition of macrophages within the tumor from immune-suppressing to immune-activating. Jounce is conducting IND enabling studies for this product.

JTX-4014

The third product in Jounce's pipeline is JTX-4014, another T-Cell targeting immunotherapy. The company filed its IND application in September 2018 and received approval to move to Phase 1 clinical trials in October 2018.

Partnerships

Celgene

In July 2016, Jounce entered into a collaboration with Celgene Corporation, which includes options to JTX-2011 and up to four early-stage programs to be selected from a defined pool of B cell, T regulatory cell, and tumor associated macrophage targets emerging from Jounce's Translational Science Platform and an additional option to equally share a checkpoint immuno-oncology program.

Funding

Series A

On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures.

Series B

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital.

Timeline

April 23, 2015

Series B

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital.

March 15, 2013

Series A funding round

On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures.

February 2013

Jounce Therapeutics raises a $47,000,000 series A round from Third Rock Ventures.

2012

Jounce Therapeutics was founded by James P. Allison, Drew Pardoll, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber and Thomas F. Gajewski.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Allison Nance

VP, Regulatory Affairs & Quality Assurance

Anna L. Barry

Senior VP, General Counsel & Secretary

Dishant Shah

Employee

Drew Pardoll

Founder

Elizabeth Trehu

Chief Medical Officer

Hugh Cole

Chief Business Officer & Head of Corporate Development

James P. Allison

Founder

Kim Drapkin

CFO

Louis M. Weiner

Founder

Michael Woodbury

Employee

Padmanee Sharma

Founder

Richard Murray

President & CEO

Robert Schreiber

Founder

Stephen Farrand

Chief Technical Officer

Ted Harding

VP, Human Resources

Thomas F. Gajewski

Founder

Further reading

Title
Author
Link
Type
Date

Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-Generation Immuno-Oncology Therapies for Patients with Cancer

Jounce Therapeutics

Web

Jounce Therapeutics Reports Third Quarter 2018 Financial Results

Jounce Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Java with Jounce Fabien Depis

July 23, 2018

The Promise of Cancer Immunotherapy

October 14, 2016

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
June 5, 2020
FierceBiotech
After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce Therapeutics.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.